Procaspase-3 activation as an anti-cancer strategy: structure− activity relationship of procaspase-activating compound 1 (PAC-1) and Its cellular co-localization with …
…, CJ Novotny, RK Totten, PJ Hergenrother
Index: Peterson, Quinn P.; Hsu, Danny C.; Goode, David R.; Novotny, Chris J.; Totten, Ryan K.; Hergenrother, Paul J. Journal of Medicinal Chemistry, 2009 , vol. 52, # 18 p. 5721 - 5731
Full Text: HTML
Citation Number: 99
Abstract
A goal of personalized medicine as applied to oncology is to identify compounds that exploit a defined molecular defect in a cancerous cell. A compound called procaspase-activating compound 1 (PAC-1) was reported that enhances the activity of procaspase-3 in vitro and induces apoptotic death in cancer cells in culture and in mouse xenograft models. Experimental evidence indicates that PAC-1 activates procaspase-3 in vitro through ...
Related Articles:
[Matarrese; Soloviev; Moresco; Todde; Simonelli; Colombo; Magni; Carpinelli; Fazio; Kienle, M. Galli Journal of Labelled Compounds and Radiopharmaceuticals, 2000 , vol. 43, # 4 p. 359 - 374]
Design and synthesis of novel CCR3 antagonists
[Gong, Leyi; Hogg, J. Heather; Collier, James; Wilhelm, Robert S.; Soderberg, Carol Bioorganic and Medicinal Chemistry Letters, 2003 , vol. 13, # 20 p. 3597 - 3600]
Design and synthesis of novel CCR3 antagonists
[Gong, Leyi; Hogg, J. Heather; Collier, James; Wilhelm, Robert S.; Soderberg, Carol Bioorganic and Medicinal Chemistry Letters, 2003 , vol. 13, # 20 p. 3597 - 3600]
[Matarrese; Soloviev; Moresco; Todde; Simonelli; Colombo; Magni; Carpinelli; Fazio; Kienle, M. Galli Journal of Labelled Compounds and Radiopharmaceuticals, 2000 , vol. 43, # 4 p. 359 - 374]
Pegaptanib for neovascular age-related macular degeneration
[Gupta; Saxena; Jain; Anand Archiv der Pharmazie, 1984 , vol. 317, # 12 p. 1010 - 1017]